Prikaz osnovnih podataka o dokumentu
Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications
dc.creator | Becarević, Mirjana | |
dc.creator | Seferović, Jelena | |
dc.creator | Ignjatović, Svetlana | |
dc.creator | Singh, Sandra | |
dc.creator | Majkić-Singh, Nada | |
dc.date.accessioned | 2019-09-02T11:25:14Z | |
dc.date.available | 2019-09-02T11:25:14Z | |
dc.date.issued | 2011 | |
dc.identifier.issn | 1043-4666 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/1552 | |
dc.description.abstract | Objective: In vitro, stimulation of monocytes with antiphospholipid (aPL) antibodies resulted in increased secretion of TNF-alpha, but association of aPL with features of diabetes mellitus is not clarified yet. Therefore, we investigated the distribution of anticardiolipin (aCL), anti-beta 2gpI (a beta 2gpI), anti-annexin A5 (aannxA5), and anti-oxLDL (aoxLDL) antibodies, and TNF-alpha in well-formed group of 78 patients with type II diabetes mellitus without vascular complications. Methods: Investigated antibodies and TNF-alpha concentrations were measured by ELISA. Results: Antiphospholipid antibodies were in positive correlation with TNF-alpha concentrations: aCL IgG (r = 0.303, p = 0.007), aCL IgM (r = 0.386, p = 0.000), a beta 2gpI IgG (r = 0.499, p = 0.000), a beta 2gpI IgM (r = 0.462, p = 0.000), aanxA5 IgG (r = 0.479, p = 0.000), aanxA5 IgM (r = 0.641, p = 0.000), aoxLDL (IgG + IgM, r = 0.279, p = 0.000). Anticardiolipin-positive and aCL-negative subgroups differed in TNF-alpha concentrations (Mann-Whitney, p = 0.032). Significantly elevated LDL concentrations were noticed in aCL-positive patients with disease duration 10-15 years (chi(2) = 15.000, p = 0.000) and apoB concentrations were elevated in aoxLDL-positive patients with disease duration 7-10 years (chi(2) = 3.938, p = 0.047). Conclusion: Significant association of antiphospholipid antibodies and TNF-alpha might be a marker of severe atherogenic profile (suggested by increased levels of lipids in aPL-positive subgroups) and should be used for the stratification of patients with an increased risk for future deterioration of the disease. | en |
dc.publisher | Academic Press Ltd- Elsevier Science Ltd, London | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175036/RS// | |
dc.rights | restrictedAccess | |
dc.source | Cytokine | |
dc.subject | Antiphospholipid antibodies | en |
dc.subject | TNF-alpha | en |
dc.subject | Diabetes mellitus type II | en |
dc.subject | Atherosclerosis | en |
dc.title | Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Сеферовић, Јелена; Игњатовић, Светлана; Мајкић-Сингх, Нада; Бецаревић, Мирјана; Сингх, Сандра; | |
dc.citation.volume | 55 | |
dc.citation.issue | 2 | |
dc.citation.spage | 301 | |
dc.citation.epage | 306 | |
dc.citation.other | 55(2): 301-306 | |
dc.citation.rank | M22 | |
dc.identifier.wos | 000293158100021 | |
dc.identifier.doi | 10.1016/j.cyto.2011.05.001 | |
dc.identifier.pmid | 21621418 | |
dc.identifier.scopus | 2-s2.0-80955179024 | |
dc.type.version | publishedVersion |